eMedClub Secures Tens of Millions of RMB in Series A Funding to Accelerate Biopharma Innovation

VCBeat (WeChat: vcbeat) has learned that on October 11, 2021, EmaiKe announced the recent completion of its Series A financing round, raising tens of millions of RMB. Participating investors included Longjin Investment, Shileng Investment, Haimaide Fund, and Fof Capital. The funds from this round will be used by EmaiKe to develop application scenarios centered on two types of B-end users—biopharmaceutical innovation companies and pharmaceutical industry supply chains—with the aim of accelerating new drug R&D, enhancing the digital brand influence of pharmaceutical companies, and boosting the competitiveness of supply chain products.

Founded in 2016, E-Pharmaceuticals (Yimaike) is a leading digital industrial service platform in the field of innovative biological drugs. Since its establishment, the company has continuously focused on cutting-edge biopharmaceutical technologies, including cell and gene therapy (CAR-T/NK, TIL, AAV, OV, LV), novel antibody drugs (Nanobody, bsAbs, ADC), stem cells and regenerative medicine (MSC, iPSC, organoids, and 3D culture), gene editing, synthetic biology, nucleic acid drugs (small nucleic acids, mRNA), novel vaccines, and novel delivery systems (LNP, exosomes, VLP). By leveraging keen information dissemination and data mining capabilities, it monitors and identifies emerging startups in the early stages of innovative biologics development. Over the past five years, E-Pharmaceuticals has engaged across the entire lifecycle of biopharmaceuticals—from new drug R&D, regulatory registration, and clinical trials to manufacturing quality control and commercialization. Through digital services such as communication strategies, content creation, industry analysis, media interviews, industrial summits, and knowledge-empowering online courses, the company has successfully helped numerous innovative biopharmaceutical enterprises and pharmaceutical supply chain partners enhance their visibility, attract investment, strengthen core product competitiveness, and drive precise digital brand marketing.

Wang Haifeng, founder of iMedClub, stated, “The development of new drugs is gradually transitioning from the era of ‘me-too’ and ‘me-better’ products to a blue-ocean era characterized by ‘first-in-class’ and ‘best-in-class’ innovations. Discovering novel targets, investigating new pharmacological mechanisms of action, exploring new indications, and pioneering new therapeutic areas have become the mainstream trends of our time. Consequently, the unique characteristics of the bio-innovative drug industry drive pharmaceutical companies and founding teams to cultivate diversified capabilities for early-stage survival: 1) Ownership of original technologies with independent intellectual property rights; 2) Capability in iterative product development that differentiates from homogeneous competition and significantly enhances efficacy; 3) Richer research experience, innovative thinking, and the courage to embrace failure; 4) Precise selection of early-stage venture capital, effective control of financing rhythms, and reasonable expansion and operational strategies; 5) Integration of industrial resources to enhance pipeline development and corporate growth capabilities. Meanwhile, an increasing number of localized and domestically produced supply chain products are striving to boost brand influence and product competitiveness. Therefore, the digital industrial service platform established by iMedClub effectively addresses the development bottlenecks faced by start-ups in this industry. We appreciate the support and expectations of the investors in this funding round for iMedClub’s future development. We will continue to root ourselves deeply in the industry, grow alongside bio-innovative drug enterprises, and strive to make iMedClub the preferred long-term strategic brand partner for bio-innovative drug companies.”

Shiling Investment is a professional investment firm specializing in the biopharmaceutical and healthcare sectors. Its investment team possesses extensive experience in equity investment, while its scientific team comprises experts with rich practical experience from major global pharmaceutical companies. Shiling Fund has consistently adhered to a value-investment philosophy centered on the biopharmaceutical and healthcare industry chains, dedicated to identifying high-quality early- to mid-stage enterprises and facilitating their rapid growth.

HiMed, the Medical Innovation Collaboration Platform, was established by 35 successful founders, investors, and professors from the medical industry in the Shanghai Zhangjiang area. Leveraging the founders’ own entrepreneurial successes and extensive industry resources, the platform specializes in medical collaboration, technology transfer, incubation, and early-stage investment. HiMed Fund is a general partner (GP) management company founded by several of these initiators, while some also participate as limited partners (LPs) in an angel investment platform. Currently, it manages two funds and has invested in more than twenty early-stage medical startup projects.

Fof Capital is research-driven and adheres to value investing, primarily focusing on the healthcare industry and advanced manufacturing, with an emphasis on early-to-mid-stage projects. To date, it has invested in multiple companies in the healthcare sector, including ImmuneOnco, TiLuo Medical, Heding Pharma, Desheng Biotech, Shiguang Hengsheng, and Taize Huikang.